Concert Pharmaceuticals Inc. (NASDAQ:CNCE) shares saw strong trading volume on Thursday . 207,459 shares traded hands during trading, an increase of 97% from the previous session’s volume of 105,186 shares.The stock last traded at $10.63 and had previously closed at $10.64.

A number of equities research analysts have recently issued reports on the company. Brean Capital reaffirmed a “buy” rating on shares of Concert Pharmaceuticals in a research report on Saturday, April 30th. Zacks Investment Research raised Concert Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Stifel Nicolaus started coverage on Concert Pharmaceuticals in a report on Friday, July 1st. They set a “buy” rating and a $23.00 price target on the stock. Two research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $26.43.

The stock’s market cap is $236.27 million. The company’s 50-day moving average price is $11.48 and its 200 day moving average price is $12.54.

Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.60) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.03. Analysts forecast that Concert Pharmaceuticals Inc. will post ($2.51) EPS for the current fiscal year.

An institutional investor recently raised its position in Concert Pharmaceuticals stock. Dimensional Fund Advisors LP raised its stake in Concert Pharmaceuticals Inc. (NASDAQ:CNCE) by 405.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 224,348 shares of the company’s stock after buying an additional 179,998 shares during the period. Dimensional Fund Advisors LP owned 1.02% of Concert Pharmaceuticals worth $4,256,000 at the end of the most recent quarter.

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.